• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BENAZEPRIL Drug Record

  • Summary
  • Interactions
  • Claims
  • BENAZEPRIL chembl:CHEMBL838 Approved

    Alternate Names:

    C09AA07
    BENAZEPRIL
    LOTENSIN
    CGS-14824A
    LOTREL
    BENAZEPRILUM
    LOTENSIN®
    1H-1-BENZAZEPINE-1-ACETIC ACID, 3-((1-(ETHOXYCARBONYL)-3-PHENYLPROPYL)AMINO)-2,3,4,5-TETRAHYDRO-2-OXO-, (S-(R*,R*))-
    CIB824
    chembl:CHEMBL838
    drugbank:00542
    chemidplus:86541-75-5
    rxcui:18867
    pubchem.compound:5362124

    Drug Info:

    Drug Class antihypertensive agents
    Year of Approval 1991
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antihypertensive agent
    (1 More Sources)

    Publications:

    Zhang Y et al., 2009, E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients., Chin Med J (Engl)
    Song et al., 2002, Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update., Clin Pharmacokinet
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    He H et al., 2005, A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril., Ann Hum Biol
    Kohno M et al., 1999, Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors., Am J Med
    Penno G et al., 1998, Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM., Diabetes
    Zee RY et al., 1998, Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis., Hypertension
    Ohmichi N et al., 1997, Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype., Am J Hypertens
    Sasaki M et al., 1996, Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiographic studies., J Hypertens
    Rudnicki M et al., 2009, Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease., Pharmacogenomics
    Arnett DK et al., 2005, Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study., Circulation
    Yu Y et al., 2005, Associations of baseline blood pressure levels and efficacy of Benazepril treatment with interaction of alpha-adducin and ACE gene polymorphisms in hypertensives., Clin Exp Hypertens
    Takahashi T et al., 2001, The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage., Respir Med
    Ha SK et al., 2000, ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus., Nephrol Dial Transplant
    Stavroulakis GA et al., 2000, Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism., Cardiovasc Drugs Ther
    Yu HM et al., 2006, Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors., Clin Pharmacol Ther
    Jiang S et al., 2005, A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study., Clin Exp Hypertens
    Jiang S et al., 2004, The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor., Thromb Res
    Huang G et al., 2004, Beta2 adrenergic receptor gene Arg16Gly polymorphism is associated with therapeutic efficacy of benazepril on essential hypertension in Chinese., Clin Exp Hypertens
    Yu H et al., 2014, A core promoter variant of angiotensinogen gene and interindividual variation in response to angiotensin-converting enzyme inhibitors., J Renin Angiotensin Aldosterone Syst
    Su X et al., 2007, Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor., Circulation
    Zhang et al., 2004, D919G polymorphism of methionine synthase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients., J. Hum. Genet.
  • BENAZEPRIL   PRCP

    Interaction Score: 17.67

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20079160


    Sources:
    PharmGKB

  • BENAZEPRIL   MTR

    Interaction Score: 5.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15148588


    Sources:
    PharmGKB

  • BENAZEPRIL   CYP11B2

    Interaction Score: 4.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16765146


    Sources:
    PharmGKB

  • BENAZEPRIL   ACE

    Interaction Score: 2.89

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name benazepril,Lotensin
    Novel drug target Established target

    PMIDs:
    11929321 11752352 15788353 10335726 9726242 9535416 9270093 8986921 19290794 15967849 15773232 11217909 11007831 10999650


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • BENAZEPRIL   AGT

    Interaction Score: 1.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25143324 17261659


    Sources:
    PharmGKB

  • BENAZEPRIL   MTHFR

    Interaction Score: 1.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16081343 15226090


    Sources:
    PharmGKB

  • BENAZEPRIL   ADRB2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15554460


    Sources:
    PharmGKB

  • TEND: BENAZEPRIL

    • Version: 01-August-2011

    Alternate Names:
    BENAZEPRIL Primary Drug Name

    Drug Info:
    Year of Approval 1991
    Drug Class antihypertensive agents

    Publications:

  • TdgClinicalTrial: BENAZEPRIL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antihypertensive agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: benazepril

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Yu HM et al., 2006, Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors., Clin Pharmacol Ther
    Zhang Y et al., 2009, E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients., Chin Med J (Engl)
    Su X et al., 2007, Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor., Circulation

  • TTD: Benazepril

    • Version: 2020.06.01

    Alternate Names:
    D0U3EC TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL838

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21